The Hemato-Immunology Research Service (SRHI) conducts research on the HLA-G molecule in the context of transplantation and oncology. At a fundamental level, the aim is to define the link between HLA-G and other immune checkpoints, in particular PD1/PDL1, and to understand the mechanisms controlling immune tolerance.
The objective of this research is to move on to clinical applications at the (i) therapeutic level, by promoting HLA-G-mediated tolerance as an anti-transplant rejection strategy, or conversely by blocking this tolerance using anti-HLA-G antibodies for antitumor treatment, and (ii) to identify new markers for prognosis and treatment efficacy.
![]()
![]()
Since 1998, the SRHI has organized the international conference on the HLA-G molecule every three years and international workshops.